A Phase 1 Study to Evaluate the Safety and Tolerability of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Subjects with Multiple System Atrophy
Latest Information Update: 21 Oct 2024
At a glance
- Drugs CS 10BR05 (Primary)
- Indications Multiple system atrophy
- Focus Adverse reactions
- Sponsors CORESTEM
Most Recent Events
- 03 Jan 2022 New trial record